Ä¢¹½AV

The news: Prescription drugmakers can now apply for new Trump administration priority review vouchers that will cut drug approval times down from 10-12 months to just 1-2 months. Our take: Good faith commitments for US drug onshoring investments could translate to valuable advantages if those drugmakers can leverage those into a CNPV. But with so many pharma companies already in that pool, we expect this year’s winners to be drugmakers who can show real evidence of two, three or even all five priorities on the Trump administration list.

YouTube is the No. 1 US media platform when it comes to time spent by US adult users, reaching 11.4 billion minutes per day in 2025.

The news: AstraZeneca plans to invest $50 billion in US drug manufacturing and R&D by 2030. The big takeaway: Pouring billions into US builds isn’t an option for most generic drugmakers that operate on thin margins. This could result in shortages since companies that make generics may have to choose between exiting the market once tariffs take effect and raising prices when possible. Other players in this space might find it most beneficial to wait it out and see if Trump changes course yet again on tariff policy.

Automakers face an increasingly difficult environment as President Donald Trump’s tariffs and the removal of EV tax credits reshape supply chains and production strategy. Like the broader US economy, auto sales have been resilient thus far, as tariffs and other government policies motivate consumers to buy now. Automakers and dealers are capitalizing on the moment with incentives like employee pricing, but the short-term surge is unlikely to last.

Turbulence in trade relations is changing how China’s ecommerce platforms do business in the US, with spillover effects on US retail and advertising.

The news: As opportunities for AI-powered ads grow, consumers remain hesitant and can even be turned off by a brand using the technology. Just 12% of US adults would be more likely to buy a product from a brand if they knew it used AI in its advertising, per CivicScience. Less than a quarter (22%) positively view brands that use AI-powered advertising, compared with 37% who view them negatively. Our take: Transparency and careful application of AI are key to avoid alienating users and build trust with consumers. Brands should introduce AI slowly by starting with prototyping ideas and generating backgrounds before diving into full-scale AI ad creation.

The news: Though it already offers software-as-a-service in the US, UK digital bank Starling has its sights set on a US expansion, per PYMNTS. Our take: Starling’s multi-pronged growth strategy is in line with its biggest digital competitors. We’ve recently covered multiple neobanks and fintechs pursuing or considering IPOs in the US, along with fintechs acquiring banks for licenses. But this isn't just about neobanks competing with other neobanks; it represents a direct strategic pivot by digital-native players to leverage their technology to rapidly modernize and capture customers from the traditional banking market. Such moves will inevitably intensify competitive pressure on US mid-tier and community banks, forcing them to seek fintech partnerships to avoid becoming acquisition targets themselves.

The news: US retail sales rose 0.6% MoM in June, per the Commerce Department, well ahead of the projected 0.1% increase. On a YoY basis, sales were up a healthy 3.9%, a sign of consumers’ resilience in the face of considerable uncertainty. Our take: June’s upbeat sales report underscores the volatility of the current retail landscape. While consumers may currently feel secure enough to manage rising prices, that could quickly change as tariff-related cost increases begin to hit more directly.